Skip to main content

UCB Australia Pty Ltd

Regulatory activities for this sponsor.

Sponsor content

12 result(s) found, displaying 1 to 10
  • Zilbrysq (zilucoplan) has been approved as an add-on to standard therapy for the treatment of generalised myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
  • Australian Public Assessment Report for Lacosamide
  • Australian Public Assessment for Certolizumab pegol
  • Australian Public Assessment Report for Brivaracetam
  • Australian Public Assessment Report for Certolizumab

Help us improve the Therapeutic Goods Administration site